Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rho kinase inhibitors: a patent review (2014 – 2016)
Olivier Defert, Sandro Boland
Expert Opinion on Therapeutic Patents (2017) Vol. 27, Iss. 4, pp. 507-515
Closed Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

ROCK inhibition in models of neurodegeneration and its potential for clinical translation
Jan Christoph Koch, Lars Tatenhorst, Anna‐Elisa Roser, et al.
Pharmacology & Therapeutics (2018) Vol. 189, pp. 1-21
Open Access | Times Cited: 190
RhoA-ROCK Signaling as a Therapeutic Target in Traumatic Brain Injury
Shalaka Mulherkar, Kimberley F. Tolias
Cells (2020) Vol. 9, Iss. 1, pp. 245-245
Open Access | Times Cited: 144
Pharmacology and Therapeutics of Bronchodilators Revisited
Maria Gabriella Matera, Clive P. Page, Luigino Calzetta, et al.
Pharmacological Reviews (2019) Vol. 72, Iss. 1, pp. 218-252
Open Access | Times Cited: 134
POAP: A GNU parallel based multithreaded pipeline of open babel and AutoDock suite for boosted high throughput virtual screening
A. Samdani, Umashankar Vetrivel
Computational Biology and Chemistry (2018) Vol. 74, pp. 39-48
Closed Access | Times Cited: 88
Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema
Akrit Sodhi, Tao Ma, Deepak Menon, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 11, pp. 4593-4608
Open Access | Times Cited: 82
Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential
Seohyun Kim, Seong A Kim, Ji-Hoon Han, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12916-12916
Open Access | Times Cited: 58
Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3
Qingfang Li, Yuan Cheng, Zhe Zhang, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 10
Open Access | Times Cited: 42
Mechanisms of Sepsis-Induced Acute Lung Injury and Advancements of Natural Small Molecules in Its Treatment
Yaxi Xu, Jianzeng Xin, Yupei Sun, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 472-472
Open Access | Times Cited: 11
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
Paul Lingor, Markus Weber, William Camu, et al.
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 71
Strategies to Reduce Oxidative Stress in Glaucoma Patients
M.D. Pinazo-Durán, Kian Shoaie-Nia, Vicente Zanón‐Moreno, et al.
Current Neuropharmacology (2017) Vol. 16, Iss. 7, pp. 903-918
Open Access | Times Cited: 70
Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Anna‐Elisa Roser, Lars Tönges, Paul Lingor
Frontiers in Aging Neuroscience (2017) Vol. 9
Open Access | Times Cited: 66
Descemet Stripping Only Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study
Gregory Moloney, Daniel Garcerant Congote, Nino Hirnschall, et al.
Cornea (2020) Vol. 40, Iss. 3, pp. 320-326
Closed Access | Times Cited: 60
The Role of Rho Kinase Inhibitors in Corneal Diseases
Stefan Futterknecht, Eleftherios Chatzimichail, Konstantin Gugleta, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 97-108
Open Access | Times Cited: 7
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus
Mario Cazzola, Paola Rogliani, Luigino Calzetta, et al.
Trends in Pharmacological Sciences (2017) Vol. 38, Iss. 10, pp. 940-951
Closed Access | Times Cited: 61
Chemical Chaperones as Novel Drugs for Parkinson’s Disease
Jordi Pujols, Samuel Peña‐Díaz, Irantzu Pallarès, et al.
Trends in Molecular Medicine (2020) Vol. 26, Iss. 4, pp. 408-421
Closed Access | Times Cited: 48
Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice
Renato Fraga Righetti, Tabata Maruyama dos Santos, Leandro do Nascimento Camargo, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 47
Rho-kinase inhibitors in the management of glaucoma
Emanuela Berrino, Claudiu T. Supuran
Expert Opinion on Therapeutic Patents (2019) Vol. 29, Iss. 10, pp. 817-827
Closed Access | Times Cited: 46
Perspectives on ROCK2 as a Therapeutic Target for Alzheimer’s Disease
Audrey J. Weber, Jeremy H. Herskowitz
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 37
Phospho-cofilin predicts efficiency of Fasudil for oral squamous cell carcinoma treatment through Yes-associated protein inhibition
Ying Wu, Yuchen Jiang, Lanxin Jiang, et al.
Archives of Oral Biology (2025), pp. 106185-106185
Closed Access
Rho kinase inhibitor fasudil reduces l‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease
Andrea López-López, Carmen M. Labandeira, José L. Labandeira‐García, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 24, pp. 5622-5641
Open Access | Times Cited: 35
Advances in the discovery of novel agents for the treatment of glaucoma
Francesco Mincione, Alessio Nocentini, Claudiu T. Supuran
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 10, pp. 1209-1225
Closed Access | Times Cited: 29
Rho-Kinase Inhibition of Active Force and Passive Tension in Airway Smooth Muscle: A Strategy for Treating Airway Hyperresponsiveness in Asthma
Yuto Yasuda, Lu Wang, Pasquale Chitano, et al.
Biology (2024) Vol. 13, Iss. 2, pp. 115-115
Open Access | Times Cited: 4
A Narrative Review of Pharmacotherapy of Glaucoma
Shalini Virani, Parveen Rewri
Future Pharmacology (2024) Vol. 4, Iss. 2, pp. 395-419
Open Access | Times Cited: 4
Exploring the potential of Rho kinase inhibitors in ophthalmology: From mechanisms to clinical practice
Jit Kai Tan, David Steel, Sajjad Ahmad, et al.
Survey of Ophthalmology (2025)
Closed Access
The future of bronchodilation: looking for new classes of bronchodilators
Mario Cazzola, Paola Rogliani, Maria Gabriella Matera
European Respiratory Review (2019) Vol. 28, Iss. 154, pp. 190095-190095
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top